David A. Siegel Cyclacel Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.56 - $1.15 $2,632 - $5,405	-4,700 Reduced 28.31%	11,900 $6,000
Q4 2022 Feb 14, 2023	SELL	$0.54 - $21.75 $1,944 - $78,300	-3,600 Reduced 17.82%	16,600 $11,000
Q3 2022 Nov 14, 2022	BUY	$1.23 - $21.9 $3,813 - $67,890	3,100 Added 18.13%	20,200 $29,000
Q2 2022 Aug 15, 2022	SELL	$6.1 - $7.15 $4,270 - $5,005	-700 Reduced 3.93%	17,100 $18,000
Q1 2022 May 16, 2022	SELL	$5.93 - $7.6 $295,314 - $378,480	-49,800 Reduced 73.67%	17,800 $54,000
Q4 2021 Feb 14, 2022	SELL	$6.04 - $8.03 $325,556 - $432,816	-53,900 Reduced 44.36%	67,600 $263,000
Q3 2021 Nov 15, 2021	BUY	$8.02 - $11.0 $879,794 - $1.21 Million	109,700 Added 929.66%	121,500 $640,000
Q2 2021 Aug 16, 2021	BUY	$7.59 - $10.48 $89,562 - $123,664	11,800 New	11,800 $70,000

Ticker CYCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,539,200
Market Cap $7.9M
Description
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combin...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.